Hu Zhengfang, Zhang Kangda, Wu Youxuan, Wang Xinyan, Zhang Zihui, Hou Xuan, Jian Minyu, Wang Yunzhen, Liu Haiyang, Wang Anxin, Han Ruquan, Liang Fa
Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.
Department of Statistics, China National Clinical Research Center for Neurological Diseases, Beijing, PR China.
BMJ Open. 2025 Jan 4;15(1):e086234. doi: 10.1136/bmjopen-2024-086234.
Preclinical studies have shown that oxygen therapy can improve ischaemic brain tissue oxygen tension, reduce reperfusion injury after revascularisation, promote neuroregeneration and inhibit inflammatory responses potentially exerting a beneficial effect after endovascular treatment (EVT) in patients with acute ischaemic stroke (AIS). However, the optimal fraction of inspired oxygen (FiO) during EVT under general anaesthesia is currently unknown. Therefore, we are conducting a randomised controlled trial (RCT) to evaluate the impact of high-concentration oxygen vs low-concentration normobaric oxygen on early neurological function after EVT.
The Oxy-TARGET trial is an ongoing prospective, open-label, parallel-design RCT being conducted at Beijing Tiantan Hospital, Capital Medical University. It aims to enrol 200 anterior circulation AIS patients undergoing EVT under general anaesthesia between February 2024 and December 2026. Eligible participants are randomly assigned at a 1:1 ratio to receive FiO=80% or FiO=30% through endotracheal intubation, with the gas flow rate set at 4 L/min. The inspiratory oxygen concentration at the tracheal intubation site (delivered FiO) was recorded concurrently. The primary outcome is the incidence of early neurological improvement (a National Institutes of Health Stroke Scale (NIHSS) score<10 points at 24±2 hours after EVT). Additional safety and efficacy parameters included the 24-hour ΔNIHSS (baseline NIHSS - NIHSS at 24-hour) score, final infarct volume at 72 hours postrandomisation, 90-day Modified Rankin Scale (mRS) score, early neurological deterioration, postoperative pulmonary complications, blood gas parameters, symptomatic intracranial haemorrhage and 90-day mortality.
Following a rigorous review process, Oxy-TARGET has received official approval from the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (KY2023-257-02). The standardised research protocol adopted in this trial is designed to enhance anaesthesiologists' understanding of respiratory management for AIS patients during EVT. The findings of this study are intended to be disseminated through publications in international peer-reviewed journals, presentations at national and international academic conferences and broad distribution via online platforms.
NCT06224426.
临床前研究表明,氧疗可提高缺血脑组织的氧张力,减少血管再通后的再灌注损伤,促进神经再生并抑制炎症反应,这可能对急性缺血性卒中(AIS)患者的血管内治疗(EVT)产生有益影响。然而,目前尚不清楚全身麻醉下EVT期间的最佳吸入氧分数(FiO)。因此,我们正在进行一项随机对照试验(RCT),以评估高浓度氧与低浓度常压氧对EVT后早期神经功能的影响。
Oxy-TARGET试验是一项正在首都医科大学附属北京天坛医院进行的前瞻性、开放标签、平行设计的RCT。其目的是纳入200例在2024年2月至2026年12月期间接受全身麻醉下EVT的前循环AIS患者。符合条件的参与者按1:1的比例随机分配,通过气管插管接受FiO = 80%或FiO = 30%的氧疗,气体流速设定为4 L/min。同时记录气管插管部位的吸入氧浓度(输送的FiO)。主要结局是早期神经功能改善的发生率(EVT后24±2小时美国国立卫生研究院卒中量表(NIHSS)评分<10分)。其他安全性和有效性参数包括24小时NIHSS变化值(基线NIHSS - 24小时时的NIHSS)评分、随机分组后72小时的最终梗死体积、90天改良Rankin量表(mRS)评分、早期神经功能恶化、术后肺部并发症、血气参数、症状性颅内出血和90天死亡率。
经过严格的审查过程,Oxy-TARGET已获得首都医科大学附属北京天坛医院伦理委员会的正式批准(KY2023 - 257 - 02)。本试验采用的标准化研究方案旨在增强麻醉医生对AIS患者EVT期间呼吸管理的理解。本研究的结果拟通过在国际同行评审期刊上发表、在国内和国际学术会议上报告以及通过在线平台广泛传播。
NCT06224426。